Senior Board Appointment

Hutchison China Meditech Limited
29 September 2006




           Hutchison China MediTech Limited ('Chi-Med') (AIM: HCM)

                   Appointment of Senior Independent Director


London, 29 September 2006: Chi-Med today announces that it has appointed Mr.
Christopher Nash, an Independent Non-executive Director of Chi-Med since the
admission of trading of its shares on AIM in May this year, as its Senior
Independent Director.


                                      Ends

Enquiries


Chi-Med                            Telephone: [phone]

Christian Hogg, CEO

Citigate Dewe Rogerson             Telephone: [phone]


Anthony Carlisle                   (07973 611 888)

Chris Gardner                      (07903 737 649)

Yvonne Alexander                   (07866 610 682)


Notes to Editors


Chi-Med is the holding company of a pharmaceutical and healthcare group based
primarily in China and was admitted to trading on the Alternative Investment
Market of the London Stock Exchange in May 2006. Chi-Med is focused on
researching, developing, manufacturing, and selling pharmaceuticals, health
supplements and other consumer health and personal care products derived from
Traditional Chinese Medicine and botanical ingredients. Its overall aim is to
draw on the untapped wealth of knowledge and history of usage in the Traditional
Chinese Medicine industry to develop products for the global market. The Company
has three complementary businesses: drug R&D, China healthcare and consumer
products.


Chi-Med is majority owned by Hutchison Whampoa Limited, an international
corporation listed on the Main Board of The Stock Exchange of Hong Kong Limited.


                      This information is provided by RNS
            The company news service from the London Stock Exchange